Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.

NDA021180: ORTHO EVRA

  • FDA application ID: NDA021180
  • Type: Labeling Revision
  • Active ingredients: ETHINYL ESTRADIOL; NORELGESTROMIN

Conditions

Interventions

We have no "intervention" data for this trial. Help us by contributing data.

Lay summary

This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute myocardial infarction (heart attack), in current users of ORTHO EVRA (norelgestromin and ethinyl estradiol contraceptive patch) compared to current users of oral levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol, with special attention to duration of use.

Documents

 

Publications

We have no "publications" for this trial. Help us by contributing data.

Registries